Anlon Healthcare, based in Rajkot, has carved a niche in manufacturing high‑purity pharmaceutical intermediates and APIs used in medications, personal care, nutraceuticals, and animal health—critical raw materials in drug production. Its IPO is a fully fresh issue of around ₹121 crore at ₹86–91 per share, with a lot size of 164 shares. Proceeds are earmarked for capacity expansion (₹30.7 crore), working capital (₹43 crore), debt reduction, and general corporate use MoneycontrolIPO Watch.
Pros Under the Hood:
Caveats to Consider:
Verdict: With expansion plans and stronger margins in sight, Anlon Healthcare shows promise—but given the high valuation, past revenue dip, location dependency, debt, and narrow client base—cautious investors may prefer to sit this one out.
Vikran Engineering, headquartered in Thane (Maharashtra), is a fast‑growing EPC firm focused on core sectors like power transmission (EHV substations, smart metering), water infrastructure, railway electrification, and solar projects. The IPO totals ₹772 crore, comprising ₹721 crore fresh issue and ₹51 crore via offer for sale, at ₹92–97 per share, with a lot size of 148 shares. The net proceeds largely support working capital and corporate needs SharescartUpstox - Online Stock and Share TradingFortune India.
Strengths That Stand Out:
Risks to Note:
Verdict: A fundamentally sound candidate with solid growth, diverse project mix, and strong credibility. Investors could consider participating for potential listing gains and long‑term growth, while remaining watchful on execution and policy risks.
Why Swastika Investmart stands out:
Q1. When do these IPOs open and list?
Both IPOs—Anlon and Vikran—open on August 26, 2025, and close on August 29. Allotment is expected by September 1, with refunds and demat credit on September 2, and listing on September 3 on BSE and NSE IPO Watch+1Sharescart.
Q2. What is the minimum investment for retail investors?
Q3. What share quotas are allocated among investor categories?
Q4. What does the grey market premium (GMP) suggest?
Vikran shows a strong grey market premium (~17–23%), indicating investor enthusiasm and possible listing upside The Economic TimesMoneycontrol. Anlon currently has no visible GMP activity The Economic Times.
Q5. Should a risk‑aware investor subscribe to both?
Anlon’s full valuation, FY 24 revenue slump, and operational concentration suggest prudence—this one could be avoided for now. Vikran, however, offers a well-balanced risk‑reward profile; investors may consider applying for potential gains and long-term infrastructure exposure.
The Anlon Healthcare IPO tells a story of niche manufacturing with potential—but shadowed by recent revenue decline, high valuation, and reliance on a single facility and a few clients. In contrast, Vikran Engineering stands out with healthy financials, diversified order book in vital sectors, and encouraging market sentiment.
For investors seeking support, clarity, and confidence in navigating these IPOs, Swastika Investmart delivers with its SEBI‑registered platform, powerful research tools, supportive customer care, and educational edge.
To explore these IPOs or your next investment opportunity with ease and authority:
Trust Our Expert Picks
for Your Investments!